3 / 66
2
nd
line Chemotherapy
2
nd
line chemotherapy agents
ORR
mPFS
mOS
Paclitaxel (phase II, n = 45)
9%
3.1 m
6.8 m
Docetaxel (phase II, n = 72)
11%
1.6 m
7.0 m
Pemetrexed (phase II, n=47)
28%
2.9 m
9.6 m
Vinflunine (phase III, n = 253)
9%
3.0 m
6.9 m
Joly F, et al. Clin Genitourin Cancer. 2009 Aug;7(2):E28-33. Choueiri TK, et al. J Clin Oncol. 2012 Feb 10;30(5):507-
12. Sweeney CJ et al. J Clin Oncol. 2006 Jul 20;24(21):3451-7.
FDA-approved treatments for 2
nd
line metastatic bladder
cancer: none!
(until 2017)